Scarica l'app Stockscreener
52.24
5.22%
-2.88
Dopo l'orario di chiusura:
52.24
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$55.12
Aprire:
$54.65
Volume 24 ore:
1.02M
Relative Volume:
1.24
Capitalizzazione di mercato:
$2.43B
Reddito:
$1.32B
Utile/perdita netta:
$175.44M
Rapporto P/E:
14.35
EPS:
3.6395
Flusso di cassa netto:
$308.08M
1 W Prestazione:
-5.57%
1M Prestazione:
-8.86%
6M Prestazione:
-27.17%
1 anno Prestazione:
-23.39%
Intervallo 1D:
$51.66
$55.40
Intervallo di 1 settimana:
$51.00
$60.14
Portata 52W:
$47.31
$87.32
Haemonetics Corp Stock (HAE) Company Profile
Nome
Haemonetics Corp
Settore
Industria
Telefono
(781) 848-7100
Indirizzo
125 SUMMER STREET, BOSTON, MA
Compare HAE vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HAE
Haemonetics Corp
|
52.24 | 2.56B | 1.32B | 175.44M | 308.08M | 3.6395 |
ABT
Abbott Laboratories
|
82.56 | 146.87B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
282.58 | 109.33B | 25.27B | 3.34B | 4.57B | 8.6358 |
MDT
Medtronic Plc
|
74.54 | 97.77B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
53.37 | 80.16B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
77.17 | 46.04B | 6.30B | 1.07B | 1.09B | 1.8406 |
Haemonetics Corp Stock (HAE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-15 | Downgrade | Needham | Buy → Hold |
| 2025-12-11 | Downgrade | Citigroup | Buy → Neutral |
| 2025-08-11 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2025-08-08 | Reiterato | Barrington Research | Outperform |
| 2025-08-08 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-07-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-06-26 | Iniziato | Robert W. Baird | Outperform |
| 2025-02-07 | Downgrade | BofA Securities | Neutral → Underperform |
| 2024-12-06 | Iniziato | JP Morgan | Overweight |
| 2024-11-08 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-09-13 | Iniziato | CL King | Buy |
| 2024-09-11 | Iniziato | BofA Securities | Neutral |
| 2024-09-10 | Iniziato | BTIG Research | Buy |
| 2024-06-12 | Aggiornamento | Needham | Hold → Buy |
| 2022-10-13 | Iniziato | Mizuho | Buy |
| 2022-01-27 | Downgrade | Needham | Buy → Hold |
| 2021-12-15 | Downgrade | Citigroup | Buy → Neutral |
| 2021-08-17 | Ripresa | Raymond James | Outperform |
| 2021-06-17 | Iniziato | Citigroup | Buy |
| 2021-05-14 | Aggiornamento | CJS Securities | Market Perform → Market Outperform |
| 2021-04-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-19 | Downgrade | CJS Securities | Market Outperform → Market Perform |
| 2021-02-03 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2021-01-21 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| 2020-11-05 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2020-05-06 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| 2020-03-31 | Aggiornamento | CJS Securities | Market Perform → Market Outperform |
| 2020-01-10 | Iniziato | Needham | Buy |
| 2019-08-07 | Reiterato | Barrington Research | Outperform |
| 2019-05-14 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2019-05-08 | Reiterato | Barrington Research | Outperform |
| 2018-08-09 | Reiterato | Barrington Research | Outperform |
| 2018-02-07 | Reiterato | Barrington Research | Outperform |
| 2018-01-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2017-11-08 | Reiterato | Barrington Research | Outperform |
| 2017-08-08 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2017-07-13 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2017-02-07 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| 2016-11-08 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2016-11-07 | Reiterato | The Benchmark Company | Hold |
| 2016-09-20 | Downgrade | CJS Securities | Market Outperform → Market Perform |
| 2016-08-15 | Downgrade | Sidoti | Buy → Neutral |
| 2016-08-02 | Reiterato | Jefferies | Buy |
| 2016-08-02 | Reiterato | The Benchmark Company | Hold |
Mostra tutto
Haemonetics Corp Borsa (HAE) Ultime notizie
TradingKey - TradingKey
Why Haemonetics Stock Is Dropping So Sharply - TipRanks
Why Haemonetics (HAE) Is Down 9.5% After Mixed FY26 Results And FY27 Outlook Reset - simplywall.st
Haemonetics Q4 Earnings Call Highlights - sharewise.com
Haemonetics Corporation (NYSE:HAE) Q4 2026 Earnings Call Transcript - Insider Monkey
A Look At Haemonetics (HAE) Valuation After Q4 Loss And Sector-Wide Medical Device Sell Off - simplywall.st
Haemonetics Earnings Call Highlights Growth Amid Headwinds - TipRanks
HAE Maintained by JP Morgan -- Price Target Lowered to $62.00 - GuruFocus
J.P. Morgan Maintains Haemonetics(HAE.US) With Hold Rating, Maintains Target Price $62 - 富途牛牛
Baird Maintains Haemonetics(HAE.US) With Buy Rating, Cuts Target Price to $67 - 富途牛牛
Haemonetics (HAE) Q4 2026 Earnings Transcript - AOL.com
Haemonetics Corporation Q4 2026 Earnings Call Summary - Yahoo Finance
Haemonetics (HAE) Reports Q4 Fiscal 2026 Revenue Growth and Posi - GuruFocus
Needham Maintains Haemonetics(HAE.US) With Hold Rating - 富途牛牛
Haemonetics (HAE) One Off Loss And Margin Hit Challenge Bullish Earnings Narrative - simplywall.st
Haemonetics Q4 FY2026 slides: earnings beat caps transformation plan - Investing.com
Earnings call transcript: Haemonetics Q4 2026 beats EPS forecast, stock surges - Investing.com
Haemonetics (HAE) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo! Finance Canada
Haemonetics reports Q4 adjusted EPS $1.29, consensus $1.27 - TipRanks
Haemonetics Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Why Haemonetics Stock Is Sliding Despite Bold Outlook - TipRanks
Q4 2026 Haemonetics Corp Earnings Call Transcript - GuruFocus
Haemonetics beats Q4 estimates, stock surges on guidance By Investing.com - Investing.com South Africa
Haemonetics beats Q4 estimates, stock surges on guidance - Investing.com
Haemonetics (HAE) Q4 Earnings and Revenues Surpass Estimates - Yahoo! Finance Canada
Earnings Flash (HAE) Haemonetics Posts Fiscal Q4 Net Revenue $346.4M, vs. FactSet Est of $336.8M - marketscreener.com
Earnings Flash (HAE) Haemonetics Posts Fiscal Q4 Adjusted EPS $1.29, vs. FactSet Est of $1.27 - marketscreener.com
HAEMONETICS ($HAE) Releases Q4 2026 Earnings - Quiver Quantitative
Haemonetics (NYSE:HAE) Reports Upbeat Q1 CY2026 - Yahoo Finance
Haemonetics: Fiscal Q4 Earnings Snapshot - WKYC
Haemonetics : 4th Quarter FY26 Supplemental Earnings Presentation - marketscreener.com
[8-K] HAEMONETICS CORP Reports Material Event - Stock Titan
Haemonetics puts quarterly results online before May 7 investor call - Stock Titan
Haemonetics earnings ahead: Can vascular closure rebound? By Investing.com - Investing.com Canada
Haemonetics earnings ahead: Can vascular closure rebound? - Investing.com
MSN Money - MSN
Haemonetics to Present at Bank of America 2026 Healthcare Conference - PR Newswire
Haemonetics Corp. Experiences Revision in Stock Evaluation Amid Competitive Market Landscape - Markets Mojo
Is It Time To Reassess Haemonetics (HAE) After Recent Share Price Swings? - simplywall.st
Earnings Preview: Haemonetics to Report Financial Results Pre-market on May 07 - 富途牛牛
Haemonetics Announces Upcoming Departure of Longtime Board Director - TipRanks
Haemonetics director Charles J. Dockendorff not standing for re-election - TradingView
Haemonetics (HAE) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Vanguard reports 2.60M-share stake in Haemonetics (HAE) via Schedule 13G - Stock Titan
North Peak Capital Management, LLC's Haemonetics Corp(HAE) Holding History - GuruFocus
Will VASCADE MVP XL’s Expanded FDA Labeling Shift Haemonetics’ (HAE) Electrophysiology Growth Narrative - Yahoo Finance
Skylands Capital LLC Sells 44,894 Shares of Haemonetics Corporation $HAE - MarketBeat
Haemonetics Corp. Experiences Revision in Its Stock Evaluation Amid Market Challenges - Markets Mojo
Will VASCADE MVP XL’s Expanded FDA Labeling and Study Data Change Haemonetics' (HAE) Interventional Narrative? - simplywall.st
Riverwater Sees Haemonetics Volatility As Plasma Gains Test Execution - simplywall.st
Peregrine Capital Management LLC Invests $2.29 Million in Haemonetics Corporation $HAE - MarketBeat
Haemonetics Corp Azioni (HAE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.34%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):